Clinical Trial Update: Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Gebasaxturev (V937) administered intravenously or intratumorally with pembrolizumab versus pembrolizumab alone in metastatic melanoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Gebasaxturev (V937)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced/Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2024-08-06